HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:
JDI 12 1395–1399.pdf400.51 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/82877

Title: Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin
Authors: Miya, Aika Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Cho, Kyu Yong Browse this author
Kawata, Shinichiro Browse this author
Nomoto, Hiroshi Browse this author →KAKEN DB
Nagai, So Browse this author →KAKEN DB
Sugawara, Hajime Browse this author
Taneda, Shinji Browse this author
Tsuchida, Kazuhisa Browse this author
Omori, Kazuno Browse this author
Yokoyama, Hiroki Browse this author
Takeuchi, Jun Browse this author
Aoki, Shin Browse this author
Kurihara, Yoshio Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: glucose variability
C-peptide
sodium–glucose co-transporter 2 inhibitor
Issue Date: 10-Aug-2021
Publisher: John Wiley & Sons
Journal Title: Journal of Diabetes Investigation
Volume: 12
Issue: 8
Start Page: 1395
End Page: 1399
Publisher DOI: 10.1111/jdi.13479
Abstract: Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor and a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with switching from a DPP‐4 inhibitor to a SGLT2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. Materials and Methods A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was conducted in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. Results ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (-29.2±28.3 vs. -20.0±24.6, respectively; P=0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P<0.01). Conclusions COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.
Rights: http://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/82877
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University